Case Number: 1:12-cv-08060-TPG-GWG
Teva delayed more than one year between answering a complaint alleging infringement of U.S. Patent No. 8,075,872 (“Heat pressing a mixture of an active ingredient with abuse potential, a high strength polymer, and a wax into a controlled release dosage form”) and seeking leave to add declaratory judgment counterclaims of invalidity and non-infringement. As the court had not yet issued a scheduling order, Judge Griesa applied Rule 15’s standard (“when justice so requires”) rather than Rule 16’s good cause standard.
Judge Griesa found Teva’s delay, stated to be based on a failure to appreciate that the ‘872 patent constituted a barrier to regulatory approval of a generic product, to be inadvertent. Inadvertence, he said, “is not a wrongdoing and not so invalid a reason for delay as to bar amendment.” He observed that Endo was defending the validity of the ‘872 patent in a trial to be held alongside the instant matter, and so prejudice to Endo would be slight.
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.